Eso, Y.; Takeda, H.; Taura, K.; Takai, A.; Takahashi, K.; Seno, H.
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Curr. Oncol. 2021, 28, 4157-4166.
https://doi.org/10.3390/curroncol28050352
AMA Style
Eso Y, Takeda H, Taura K, Takai A, Takahashi K, Seno H.
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology. 2021; 28(5):4157-4166.
https://doi.org/10.3390/curroncol28050352
Chicago/Turabian Style
Eso, Yuji, Haruhiko Takeda, Kojiro Taura, Atsushi Takai, Ken Takahashi, and Hiroshi Seno.
2021. "Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma" Current Oncology 28, no. 5: 4157-4166.
https://doi.org/10.3390/curroncol28050352
APA Style
Eso, Y., Takeda, H., Taura, K., Takai, A., Takahashi, K., & Seno, H.
(2021). Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology, 28(5), 4157-4166.
https://doi.org/10.3390/curroncol28050352